Table 2.
Current clinical trials for chemotherapy-induced peripheral neuropathy (CIPN).
| Study Title | Identifier | Sponsor | Phase | Chemo-Therapeutics | Cancer Type | Intervention |
|---|---|---|---|---|---|---|
| Drug repurposing for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) | NCT04780854 | Cairo University | Phase 2 | Paclitaxel | NS | Metformin vs. placebo |
| The preliminary effects of henna on CIPN | NCT04201587 | Selcuk University | NA | NS | NS | Henna application vs. control |
| Effect of tro19622 in the treatment of patients with chemotherapy-induced peripheral neuropathy (CIPN) | NCT00876538 | Hoffmann-La Roche | Phase 2 | Taxanes | NS | Olesoxime (TRO19622) vs. placebo |
| Niagen and persistent chemotherapy-induced peripheral neuropathy | NCT04112641 | University of Iowa | Phase 2 | Taxanes or Platinum | NS | Nicotinamide riboside vs. placebo capsules |
| Suncist: a study of calmangafodipir in healthy Japanese and Caucasian subjects | NCT03430999 | Pledpharma AB | Phase 1 | NA | NA | Calmangafodipir vs. placebo |
| Pregabalin in CIPN | NCT02394951 | Washington University School of Medicine | NA | Oxaliplatin, Paclitaxel, Docetaxel, or their combinations | NS | Pregabalin vs. placebo |
| Preventive treatment of oxaliplatin-induced peripheral neuropathy in metastatic colorectal cancer (polar-m) | NCT03654729 | Pledpharma AB | Phase 3 | mFOLFOX6 | Metastatic colorectal cancer | Calmangafodipir (2 dosages) vs. placebo |
| A study to assess the efficacy and safety of oxycodone/naloxone in Korean patients with chemotherapy-induced peripheral neuropathy (CIPN) | NCT01675531 | Mundipharma Korea Ltd. | Phase 4 | NS | NS | Targin (oxycodone/naloxone) |
| Effect of hemp-CBD on patients with CIPN | NCT04398446 | Main Line Health | Phase 2 | NS | Non-metastatic breast, uterine, ovarian, or colorectal cancers | Hemp-based cannabidiol vs. placebo |
| Preventive treatment of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer | NCT04034355 | Pledpharma AB | Phase 3 | mFOLFOX6 | Colorectal cancer | Calmangafodipir vs. placebo |
| Ozone therapy in chemotherapy-induced peripheral neuropathy: RCT (O3NPIQ) | NCT04299893 | Bernardino Clavo | Phase 2, Phase 3 | NS | NS | Ozone vs. oxygen |
| Duloxetine and neurofeedback training for the treatment of chemotherapy induced peripheral neuropathy | NCT04560673 | M.D. Anderson Cancer Center | Phase 2 | NS | Hematopoietic, lymphoid cell, or solid malignant neoplasms | Duloxetine vs. neurofeedback training vs. their combination |
| Study of nicotine for pain associated with chemotherapy-induced peripheral neuropathy | NCT04468230 | Virginia Commonwealth University | Phase 2 | NS | NS | Nicotine transdermal patch |
| Menthol in neuropathy trial (MINT) | NCT04276727 | University of Edinburgh | Phase 2 | NS | NS | Menthol vs. placebo |
| Minocycline hydrochloride in reducing chemotherapy-induced peripheral neuropathy and acute pain in patients with breast cancer undergoing treatment with paclitaxel | NCT02297412 | Academic and Community Cancer Research United | Phase 2 | Paclitaxel | Breast cancer | Minocycline hydrochloride vs. placebo |
| High dose inorganic selenium for preventing chemotherapy-induced peripheral neuropathy | NCT04201561 | Seoul National University Hospital | Phase 3 | Paclitaxel | Response evaluation criteria in solid tumors (RECIST), or gynecologic, epithelial ovarian, fallopian, or primary peritoneal cancers | Sodium selenite pentahydrate vs. vehicle vs. standard care |
| Chemotherapy-induced peripheral neuropathy-essential oil intervention | NCT03449303 | Augusta University | NA | NS | Breast cancer | Eoi (10% dilution of Curcuma longa, Piper nigrum, Pelargonium asperum, Zingiber officinale, Mentha X piperita, and Rosmarinus officinalis Ct. Cineole in (Simmondsia chinensis) vs. placebo (Simmondsia chinensis) |
| The role of transient receptor potential channels in chemotherapy-induced peripheral neuropathic pain | NCT04415892 | Universitaire Ziekenhuizen Leuven | NA | Paclitaxel or Oxaliplatin | NS | Cinnamaldehyde and capsaicin |
| Cannabinoids for taxane-induced peripheral neuropathy | NCT03782402 | New York State Psychiatric Institute | Phase 2 | Paclitaxel or Docetaxel | Breast cancer | Cannabinoids of various strengths |
| N-acetyl cysteine effect in peripheral neuropathy in cancer patients | NCT03492047 | Ain Shams University | Phase 1, Phase 2 | Paclitaxel | Breast cancer | N-acetylcysteine (low vs. high dose) vs. standard care |
| Lidocaine versus duloxetine for the prevention of taxane-induced peripheral neuropathy in breast cancer patients | NCT04732455 | Gamal Mohamed Taha Abouelmagd | NA | Taxanes | Breast cancer | Lidocaine vs. vehicle vs. duloxetine |
| The potential protective role of venlafaxine versus memantine in paclitaxel-induced peripheral neuropathy | NCT04737967 | Mendel AI | Phase 2, Phase 3 | Paclitaxel | NS | Venlafaxine vs. memantine |
| NR in chemo-induced peripheral neuropathy | NCT03642990 | Donna Hammond | Phase 2 | Paclitaxel | Metastatic breast cancer | Nicotinamide riboside |
| NR in chemo-induced peripheral neuropathy | NCT03642990 | Donna Hammond | Phase 2 | Platinum | Platinum-resistant recurrent ovarian, peritoneal, endometrial, fallopian tube, or head and neck cancers | Nicotinamide riboside |
| Duloxetine in treating peripheral neuropathy caused by chemotherapy in patients with cancer | NCT00489411 | Alliance for Clinical Trials in Oncology | Phase 3 | Taxanes or Platinum | NS | Duloxetine hydrochloride vs. placebo |
| Vitamin e in preventing peripheral neuropathy caused by chemotherapy in patients receiving chemotherapy for cancer | NCT00363129 | Alliance for Clinical Trials in Oncology | Phase 3 | Taxanes or Platinum | NS | Vitamin E vs. placebo |
| Lamotrigine in treating peripheral neuropathy caused by chemotherapy in patients with cancer | NCT00068445 | Alliance for Clinical Trials in Oncology | Phase 3 | Taxanes, Platinum, Vinca Alkaloids | NS | Lamotrigine vs. placebo |
| Clinical study on acetyl-l-carnitine | NCT01526564 | Lee's Pharmaceutical Limited | Phase 3 | Taxoids, Satraplatin and Vincristine | NS | Acetylcarnitine vs. placebo |
| Gabapentin in treating peripheral neuropathy in cancer patients undergoing chemotherapy | NCT00027963 | Alliance for Clinical Trials in Oncology | Phase 3 | Taxanes, Platinum, or Vinca alkaloids | NS | Gabapentin vs. placebo |
| Baclofen-amitriptyline hydrochloride-ketamine gel in treating peripheral neuropathy caused by chemotherapy in patients with cancer | NCT00516503 | Alliance for Clinical Trials in Oncology | Phase 3 | NS | Chronic myeloproliferative disorders, leukemia lymphoma, lymphoproliferative disorder, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms | Baclofen/amitriptyline/ketamine gel vs. placebo |
| Fingolimod in treating patients with chemotherapy-induced neuropathy | NCT03943498 | Mayo Clinic | Early Phase 1 | NS | NS | Fingolimod vs. Fingolimod hydrochloride |
Abbreviations: NA, not applicable; NS, not specified.